Have a feature idea you'd love to see implemented?
Let us know!
PLX Protalix BioTherapeutics Inc
Price (delayed)
$1.76
Market cap
$129.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.15
Enterprise value
$107.87M
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to
Highlights
PLX's debt has plunged by 78% from the previous quarter and by 78% YoY
PLX's EPS is up by 32% since the previous quarter
PLX's net income has dropped by 190% year-on-year but it is up by 35% since the previous quarter
The gross profit has dropped by 65% year-on-year but it is up by 34% since the previous quarter
Key stats
What are the main financial stats of PLX
Market
Valuations
Earnings
Shares outstanding
73.63M
Market cap
$129.6M
Enterprise value
$107.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.99
Price to sales (P/S)
2.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.36
Revenue
$45.67M
Gross profit
$16.38M
Net income
-$9.61M
EBIT
-$9.04M
EBITDA
-$7.76M
Free cash flow
$7.17M
Per share
Balance sheet
Liquidity
EPS
-$0.15
EPS diluted
-$0.13
Free cash flow per share
$0.1
Book value per share
$0.44
Revenue per share
$0.62
TBVPS
$0.84
Total assets
$61.56M
Total liabilities
$29.13M
Debt
$5.68M
Equity
$32.44M
Working capital
$23.63M
Debt to equity
0.18
Current ratio
1.98
Quick ratio
1.22
Net debt/EBITDA
2.8
Margins
Efficiency
Dividend
EBITDA margin
-17%
Gross margin
35.9%
Net margin
-21%
Operating margin
-19.5%
Return on assets
-11.7%
Return on equity
-30.9%
Return on invested capital
-28.3%
Return on capital employed
-24.2%
Return on sales
-19.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLX stock price
How has the Protalix BioTherapeutics stock price performed over time
Intraday
1.15%
1 week
-2.22%
1 month
4.14%
1 year
2.92%
YTD
-1.12%
QTD
72.55%
Financial performance
How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$45.67M
Gross profit
$16.38M
Operating income
-$8.91M
Net income
-$9.61M
Gross margin
35.9%
Net margin
-21%
The operating margin has plunged by 192% YoY but it has increased by 50% from the previous quarter
PLX's net income has dropped by 190% year-on-year but it is up by 35% since the previous quarter
Protalix BioTherapeutics's operating income has shrunk by 166% YoY but it has increased by 40% QoQ
The gross profit has dropped by 65% year-on-year but it is up by 34% since the previous quarter
Growth
What is Protalix BioTherapeutics's growth rate over time
Valuation
What is Protalix BioTherapeutics stock price valuation
P/E
N/A
P/B
3.99
P/S
2.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.36
PLX's EPS is up by 32% since the previous quarter
PLX's P/B is 29% above its last 4 quarters average of 3.1
Protalix BioTherapeutics's equity has decreased by 15% YoY but it has increased by 13% QoQ
PLX's price to sales (P/S) is 66% higher than its 5-year quarterly average of 1.7 and 57% higher than its last 4 quarters average of 1.8
Protalix BioTherapeutics's revenue has decreased by 28% YoY but it has increased by 20% from the previous quarter
Efficiency
How efficient is Protalix BioTherapeutics business performance
PLX's return on sales has dropped by 192% year-on-year but it is up by 48% since the previous quarter
The return on invested capital has dropped by 187% year-on-year but it has increased by 21% since the previous quarter
The ROA has plunged by 182% YoY but it has grown by 30% from the previous quarter
Protalix BioTherapeutics's return on equity has shrunk by 149% YoY but it has increased by 31% QoQ
Dividends
What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLX.
Financial health
How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 111% greater than its total liabilities
The total liabilities has plunged by 54% from the previous quarter and by 41% YoY
The company's current ratio rose by 49% QoQ and by 19% YoY
PLX's debt is 82% less than its equity
The debt to equity has dropped by 80% since the previous quarter and by 74% year-on-year
PLX's debt has plunged by 78% from the previous quarter and by 78% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.